Different metabolic and clinical profiles between patients with pure Alzheimer dementia and epileptic Alzheimer dementia: a metabolic study

Basit Öğe Kaydı
dc.contributor.authorOktem, Ece Ozdemir
dc.contributor.authorKadak, Kübra Soğukkanlı
dc.contributor.authorCakır, Tansel
dc.contributor.authorÖzşimşek, Ahmet
dc.contributor.authorCankaya, Seyda
dc.contributor.authorHanoğlu, Lütfü
dc.date.accessioned2026-01-24T12:00:50Z
dc.date.available2026-01-24T12:00:50Z
dc.date.issued2022
dc.departmentAlanya Alaaddin Keykubat Üniversitesi
dc.description.abstractAim: To investigate the clinical characteristics and cerebral FDG PET metabolisms of dementia patients who were also diagnosed with epilepsy and compare the differences with pure Alzheimer dementia patients.Methods: In this case-control study, a total of 14 patients, 7 patients with pure Alzheimer disease as a control group and 7 age and gender-matched patients with Alzheimer disease and concomitant epilepsy as a study group, were included. Detailed neurocognitive battery and brain fludeoxyglucose positron emission tomography (FDG PET-CT) were performed for all subjects.Results: In comparison of neurocognitive test scores, there was no significant difference between the study and control groups. However, geriatric depression scale scores were significantly lower in study group than the controls (p= 0.026). In cerebral FDG-PET CT profiles of subjects we detected significantly lower metabolism in left and right cerebellum, left lentiform nucleus, right thalamus and vermis in the study group (p=0.008, p=0.023, p=0.003, p=0.002, p=0.002, respectively). In the right parietotemporal cortex and right and left associative visual cortex, we found higher metabolism in the study group than controls (p=0.023, p=0.012, p=0.003, respectively).Conclusion: Epileptic patients with Alzheimer’s dementia may have distinct clinical and metabolic profiles, than pure Alzheimer’s disease patients. Even if there is no difference in the neurocognitive clinical scores of the patients, depression and related functional abnormalities may be a biomarker of epileptic AD.
dc.identifier.doi10.30565/medalanya.1195485
dc.identifier.endpage306
dc.identifier.issn2587-0319
dc.identifier.issue3
dc.identifier.startpage301
dc.identifier.trdizinid1216480
dc.identifier.urihttps://search.trdizin.gov.tr/tr/yayin/detay/1216480
dc.identifier.urihttps://doi.org/10.30565/medalanya.1195485
dc.identifier.urihttps://hdl.handle.net/20.500.12868/3735
dc.identifier.volume6
dc.indekslendigikaynakTR-Dizin
dc.language.isoen
dc.relation.ispartofActa Medica Alanya
dc.relation.publicationcategoryMakale - Ulusal Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.snmzKA_TR-Dizin_20260121
dc.subjectDepression
dc.subjectepilepsy
dc.subjectmetabolism
dc.subjectAlzheimer disease
dc.subjectFDG-PET CT
dc.titleDifferent metabolic and clinical profiles between patients with pure Alzheimer dementia and epileptic Alzheimer dementia: a metabolic study
dc.typeArticle

Dosyalar

Koleksiyon

TR-Dizin İndeksli Yayınlar Koleksiyonu
Acta Medica Alanya Koleksiyonu